Quantum-Si (NASDAQ:QSI – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02, FiscalAI reports. Quantum-Si had a negative return on equity of 47.12% and a negative net margin of 6,138.26%. The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.27 million.
Here are the key takeaways from Quantum-Si’s conference call:
- Quantum-Si said Proteus remains on track for a second-quarter 2027 launch. It reported that instrument design is complete, variability issues are substantially addressed, and manufacturing of the next development build is underway, with initial instruments expected this quarter.
- The company has demonstrated detection of 19 amino acids and expects to demonstrate the 20th by year-end, with all 20 targeted for launch. At World HUPO, interim Proteus results showed about 30 times more sequencing output per chamber than Platinum Pro and a lower false discovery rate, though management said the product is still in development.
- Quantum-Si has held Proteus Roadshow events in more than 35 cities and launched a pre-order program offering priority access and pricing. Management described prospective-customer interest as encouraging and said the sales funnel includes both existing users and new accounts, but did not disclose order numbers.
- Revenue fell to $212,000 from $552,000 year over year in the quarter, and the company reiterated full-year 2026 revenue guidance of about $1 million as customers await Proteus. Quantum-Si reported $149.4 million in cash, equivalents and marketable securities and said it expects funding to last into the fourth quarter of 2028.
- The company lowered its 2026 adjusted operating expense outlook to $87 million or less from $98 million or less and cash-use outlook to $87 million or less from $93 million or less, citing cost actions and discipline. It is also ordering long-lead components earlier amid AI-related supply constraints, which may increase near-term working capital needs; management said it does not currently expect the constraints to affect the launch timeline.
Quantum-Si Trading Up 13.7%
Shares of NASDAQ:QSI traded up $0.16 on Friday, hitting $1.33. The company had a trading volume of 8,206,582 shares, compared to its average volume of 9,981,961. Quantum-Si has a 1-year low of $0.69 and a 1-year high of $1.81. The stock has a market cap of $291.11 million, a price-to-earnings ratio of -3.41 and a beta of 3.26. The stock has a 50 day moving average price of $1.09 and a 200 day moving average price of $0.97.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on QSI. Weiss Ratings raised shares of Quantum-Si from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. Wall Street Zen raised shares of Quantum-Si from a “sell” rating to a “hold” rating in a research report on Tuesday, October 27th. HC Wainwright set a $4.00 target price on shares of Quantum-Si in a report on Friday, October 9th. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Quantum-Si in a research report on Friday, August 14th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $2.50.
Check Out Our Latest Research Report on Quantum-Si
About Quantum-Si
Quantum-Si Incorporated (NASDAQ:QSI) is a life sciences technology company focused on transforming protein analysis through next-generation proteomics. The company develops tools designed to identify and characterize proteins at the single-molecule level, with potential applications in drug discovery, translational research, diagnostics development and precision medicine.
Its primary offering is the Platinum platform, which combines a benchtop sequencing instrument, semiconductor-based technology, consumables and data-analysis software.
Read More
- Five stocks we like better than Quantum-Si
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Quantum-Si Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum-Si and related companies with MarketBeat.com's FREE daily email newsletter.
